C-EOYZTOR Therapeutics
mTORC1 inhibition, fixed-dose combination, neuroinflammation
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EOYZ
C-EOYZC-EOYZmTORC1 inhibition, fixed-dose combination, neuroinflammation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
TOR Therapeutics mTORC1 inhibition, fixed-dose combination, neuroinflammation
TOR Therapeutics was founded in 2015 by physicians Jeffrey Melin and Nancy Young to treat neurodegenerative disease. The company is developing RMF, an experimental oral once-daily fixed-dose combination of two mTORC1 inhibitors, initially focused on Alzheimer's disease. Its stated goal is to maintain cognitive function in early patients and target other disorders driven by mTORC1 hyperactivation.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
TOR Therapeutics — Far from goals · Bottom quartile. Derived deterministically from 1 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic